Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Posted by on Jun 17th, 2026

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $55.00.

A number of equities research analysts recently weighed in on SLN shares. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 18th. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st.

View Our Latest Stock Report on SLN

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC grew its position in Silence Therapeutics by 48.0% in the 4th quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after purchasing an additional 500,000 shares during the last quarter. Cantor Fitzgerald L. P. grew its position in Silence Therapeutics by 1.6% in the 3rd quarter. Cantor Fitzgerald L. P. now owns 801,306 shares of the company’s stock worth $4,159,000 after purchasing an additional 12,267 shares during the last quarter. Millennium Management LLC grew its position in Silence Therapeutics by 121.0% in the 4th quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after purchasing an additional 361,080 shares during the last quarter. UBS Group AG grew its position in Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after purchasing an additional 78,854 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in Silence Therapeutics by 11.8% in the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock worth $1,511,000 after purchasing an additional 30,358 shares during the last quarter. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Down 4.1%

Shares of NASDAQ:SLN opened at $6.71 on Wednesday. Silence Therapeutics has a fifty-two week low of $4.19 and a fifty-two week high of $8.40. The firm has a 50-day simple moving average of $6.74 and a 200 day simple moving average of $6.10. The company has a market cap of $316.98 million, a PE ratio of -4.22 and a beta of 1.48.

Silence Therapeutics (NASDAQ:SLN – Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. The business had revenue of $0.42 million for the quarter, compared to the consensus estimate of $1.26 million. As a group, research analysts forecast that Silence Therapeutics will post -0.95 EPS for the current fiscal year.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

Read More

Analyst Recommendations for Silence Therapeutics (NASDAQ:SLN)

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.